Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival

Journal of Pathology

Volumn 188, Issue 4, 1999, Pages 369-377

  Decaussin, Myriam ^a,b   Sartelet, Hervé ^a,b   Robert, Catherine ^a,b   Moro, Denis ^a,b   Claraz, Christine ^a,b   Brambilla, Christian ^a,b   Brambilla, Elisabeth ^a,b,c  

^a HÔPITAL MICHALLON   (France)

^b INSTITUT ALBERT BONNIOT   (France)

^c Laboratoire de Pathologie Cellulaire   (France)

Author keywords

Angiogenesis; Flk1; Flt1; Lung carcinoma; Microvessel count; Vascular endothelial growth factor; Vascular endothelial growth factor receptors

Indexed keywords

RECEPTOR SUBTYPE; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

EID: 0032787305     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199908)188:4<369::AID-PATH381>3.0.CO;2-X     Document Type: Article

References (38)

1. Boring CC, Squires TS, Tong T. Cancer statistics. Chem. Abstr. 1994; 44: 7-26.
2. Mountain CF. New international staging system for lung cancer. Chest 1986; 89: 225s-233s.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med 1995; 1: 27-31.
4. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
5. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 1998; 184: 119-122.
6. Fallowfield ME, Cook MG. The vascularity of primary cutaneous melanoma. J Pathol 1991; 164: 241-244.
7. Maeda K., Chung YS, Takatsuka S, et al. Tumor angiogenesis and tumor cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 1995; 72: 319-323.
8. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15: 2858-2865.
9. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992; 340: 145-146.
10. Harpole DH, Richards WG, Herndon JE II, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 1996; 61: 1470-1476.
11. Duarte IG, Bufkin BL, Pennington MF. et al. Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 1998; 115: 652-658.
12. Apolinario RM, Van der Valk P, De Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997; 15: 2456-2466.
13. Giatromanolaki A, Koukourakis M, O'Byrne K, et al. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 1996; 179: 80-88.
14. Giatromanolaki A, Koukourakis MI, Theodossiou D, et al. Comparative evaluation of angiogenesis assessment with anti-Factor VIII and CD31 immunostaining in non-small cell lung cancer. Clin Cancer Res 1997; 3: 2485-2492.
15. Fontanini G, Vignati S, Bigini D, et al. Neoangiogenesis: a putative marker of malignancy in non-small-cell lung cancer (NSCLC) development. Int J Cancer 1996; 67: 615-619.
16. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognsotic indicator of survival in non-small cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89: 881-886.
17. Yuan A, Yang PC, Yu CJ, et al. Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med 1995; 152: 2157-2162.
18. Angeletti CA, Lucchi M, Fontanini G, et al. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Cancer 1996; 78: 409-415.
19. Yamazaki K, Shosaku A, Takekawa H, et al. Tumor angiogenesis in human lung adenocarcinoma. Cancer 1994; 74: 2245-2250.
20. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth, microvascular hyperpermeability, and angiogenesis: review. Am Med J 1995; 146: 1029-1039.
21. Ferrara N. Vascular endothelial growth factor. Trends Cardiovasc Med 1993; 3: 244-250.
22. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844.
23. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57: 5281-5285.
24. Dobbs SP, Hewett PW, Johnson IR, Carmichael J, Murray JC. Angiogenesis is associated with vascular endothelial growth factor expression in expression in cervical intraepithelial neoplasia. Br J Cancer 1997; 76: 1410-1415.
25. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Lee ME. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-3968.
26. Mattem J, Koomägi R, VoIm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996; 73: 931-934.
27. Fontanini G, Vignati S, Bigini D, et al. Neoangiogenesis and P53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 1997; 75: 1295-1301.
28. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung carcinoma: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998; 115: 1007-1014.
29. Shibusa T, Shijubo N, Abe S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung carcinoma. Clin Cancer Res 1998; 4: 1483-1487.
30. Brambilla E, Moro D, Veale D, et al. Basaloid carcinomas of lung: a new phenotypic entity with prognostic significance. Hum Pathol 1992; 23: 993-1003.
31. Fox SB, Leek RD, Weekes MP, et al. Quantification and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 1995; 177: 275-283.
32. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A: 2474-2484.
33. De Jong JS, Van Diest PJ, Van der Valk P, Baak J. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. II: Correlation with proliferation and angiogenesis. J Pathol 1998; 184: 53-57.
34. Fong GH, Rossant J, Gertsenstein M, Beritman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70.
35. Shalaby F, Rossant J, Yamaguchi RP, et al. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature 1995; 376: 62-66.
36. De Jong JS, Van Diest PJ, Van der Valk P, Baak J. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol 1998; 184: 44-52.
37. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from Flt tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995; 10: 135-147.
38. Goldman CK, Kendall RL, Cabrere G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998; 95: 8795-8800.